EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment Failure

Mohammad Ahsen Soomro, Mohamed Ahmed, Al Ola Abdallah, Nausheen Ahmed, Jeries Kort

Clinical Lymphoma Myeloma and Leukemia · 2026-07 · 26 (7) · e853-e867

DOI: 10.1016/j.clml.2026.04.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-07. Verfasst von Mohammad Ahsen Soomro und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, PA. Electronic address: soomrom@thewrightcenter.org. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, B-Cell Maturation Antigen, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 77 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for heavily pretreated multiple myeloma, achieving unprecedented response rates in patients with otherwise dismal outcomes. However, the vast majority of patients eventually relapse due to complex resistance mechanisms. These include antigen-dependent escape-such as loss of the BCMA target through genetic deletion, epitope-level mutation, or antigen downregulation via shedding and trogocytosis-as well as antigen-independent tumor adaptations like clonal evolution and lineage plasticity that allow myeloma cells to evade immune clearance despite retaining BCMA. In addition, intrinsic CAR T-cell dysfunction (poor expansion, early exhaustion, and limited persistence) and an immunosuppressive bone marrow microenvironment (enriched in regulatory T cells, myeloid-derived suppressor cells, inhibitory cytokines, and physical sanctuary sites) critically limit long-term efficacy. We propose an integrated framework linking resistance biology to clinical relapse patterns. Finally, we review emerging strategies to overcome resistance, including dual-targeted CAR T-cell designs, enhanced CAR T engineering for improved fitness and persistence, combination approaches to boost antigen density, and novel salvage therapies targeting alternative antigens. These advancements lay the groundwork for more durable remissions and personalized immunotherapeutic interventions in multiple myeloma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunotherapy, AdoptiveB-Cell Maturation AntigenDrug Resistance, NeoplasmReceptors, Chimeric AntigenHumansTreatment FailureTumor Microenvironment

Stichwörter der Autor:innen

Immunotherapy ResistancePlasma Cell DyscrasiaResistance MechanismsTreatment FailureTumor Microenvironment

Substanzen

B-Cell Maturation AntigenTNFRSF17 protein, humanReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, PA. Electronic address: soomrom@thewrightcenter.org.
  • Department of Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, PA.
  • Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Kansas City, KS.

Zitieren

APA

Soomro, M. A., Ahmed, M., Abdallah, A. O., Ahmed, N., & Kort, J. (2026). Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment Failure. Clinical Lymphoma Myeloma and Leukemia, 26(7), e853-e867. https://doi.org/10.1016/j.clml.2026.04.004

Vancouver

Soomro MA, Ahmed M, Abdallah AO, Ahmed N, Kort J. Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment Failure. Clinical Lymphoma Myeloma and Leukemia. 2026;26(7):e853-e867. doi:10.1016/j.clml.2026.04.004

BibTeX
@article{Soomro2026,
  author = {Soomro, Mohammad Ahsen and Ahmed, Mohamed and Abdallah, Al Ola and Ahmed, Nausheen and Kort, Jeries},
  title = {Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment Failure},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {7},
  pages = {e853--e867},
  doi = {10.1016/j.clml.2026.04.004}
}
Kostenlos starten →